scholarly journals Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer

Vaccine ◽  
1996 ◽  
Vol 14 (16) ◽  
pp. 1485-1494 ◽  
Author(s):  
M Boursnell
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer

The Lancet ◽  
1996 ◽  
Vol 347 (9014) ◽  
pp. 1523-1527 ◽  
Author(s):  
L.K Borysiewicz ◽  
A Fiander ◽  
M Nimako ◽  
S Man ◽  
G.W.G Wilkinson ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia ◽  
E6 And E7 ◽  
E7 Proteins

scholarly journals A recombinant human papillomavirus (HPV) type 16 L1–vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles

1999 ◽  
Vol 80 (9) ◽  
pp. 2471-2475 ◽  
Author(s):  
Dianne Marais ◽  
Jo-Ann Passmore ◽  
James Maclean ◽  
Robert Rose ◽  
Anna-Lise Williamson
Keyword(s):  
Human Papillomavirus ◽  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Cell Mediated Immunity ◽  
Hpv 16 ◽  
Recombinant Vaccinia ◽  
Virus Like Particles ◽  
Virus Challenge ◽  
Cell Mediated Immune Response ◽  
Prophylactic Vaccines

Human papillomavirus (HPV) virus-like particles (VLP) are emerging as the immunogen of choice for prophylactic vaccines. The inability to infect animals with HPV has prevented the testing of potential vaccines such as these in animal systems. This study describes the development of a recombinant vaccinia virus (VV)–HPV type 16 (HPV-16) VLP challenge model to evaluate the efficacy of the cell-mediated immune response following HPV-16 VLP immunization in mice. Inoculation of BALB/c and C57 BL/6 mice with HPV-16 VLP resulted in HPV VLP-specific T cell proliferative responses characterized by the production of both Th1 and Th2 cytokines, and afforded protection against virus challenge from recombinant VV expressing HPV-16 L1 (VVL1R-16). Protection was demonstrated by a 4·6 log10 reduction in ovarian titres of VVL1R-16 in vaccinated BALB/c mice and a 2·3 log10 reduction in vaccinated C57 BL/6 mice, compared with unvaccinated mice.

Anti-tumoral Effect of Recombinant Vaccinia Virus through US Guided Injection in a Rabbit Model of Hepatic VX2 Carcinoma

2006 ◽  
Vol 54 (2) ◽  
pp. 103 ◽  
Author(s):  
Jong Young Oh ◽  
Byeong Ho Park ◽  
Myong Jin Kang ◽  
Jin Han Cho ◽  
Jong Cheol Choi ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Rabbit Model ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia ◽  
Vx2 Carcinoma

Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

1988 ◽  
Vol 62 (1) ◽  
pp. 176-180 ◽  
Author(s):  
S L Hu ◽  
G D Plowman ◽  
P Sridhar ◽  
U S Stevenson ◽  
J P Brown ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Human Melanoma ◽  
Recombinant Vaccinia
Sign in / Sign up

Export Citation Format

Share Document